Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Zilovertamab is a Humanised Monoclonal ROR1 Antibody - Network of ...
Zilovertamab Vedotin – Application in Therapy and Current Clinical Research
U.S. FDA approves Phase 3 Study Design for Zilovertamab in the ...
Zilovertamab vedotin (VLS-101) 靶向ROR1的抗体药物偶联物（ADC） - 哔哩哔哩
Study of Zilovertamab Vedotin and Drug Combination for Untreated ...
The addition of zilovertamab vedotin to standard R-GemOx generated ...
(PDF) Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid ...
A phase 1b study of zilovertamab in combination with paclitaxel for ...
Study on the Safety and Effectiveness of Zilovertamab Vedotin for ...
Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers ...
Zilovertamab inhibits Wnt5a-induced venetoclax-resistance and ...
Zilovertamab Vedotin + R-CHP for Diffuse Large B-Cell Lymphoma Clinical ...
The effect of zilovertamab ("zilo") +/− Paclitaxel, Cisplatin, Olaparib ...
(PDF) A phase 1b study of zilovertamab in combination with paclitaxel ...
Zilovertamab (UC-961) | ROR1 Inhibitor | MedChemExpress
The Anti-ROR1 Monoclonal Antibody Zilovertamab Inhibits the ...
Zilovertamab vedotin(Zilovertamab vedotin) - 药物靶点：ROR1 x Tubulin_在研适应症 ...
Where to Buy Zilovertamab vedotin
Phase 3 Study to Evaluate Ibrutinib Plus Zilovertamab for R/R MCL Treatment
Zilovertamab Vedotin in Mantle Cell Lymphoma: Promising Results from ...
Phase 3 waveLINE-010 Study Starts for Zilovertamab Vedotin in DLBCL
Zilovertamab Vedotin Monotherapy for Patients with Relapsed or ...
Merck’s Investigational Zilovertamab Vedotin Showed Promising Antitumor ...
Combination Zilovertamab Vedotin and R-GemOx is Safe, Effective in R/R ...
Phase 3 waveLINE-010 Study Starts for Zilovertamab Vedotin in DLBCL ...
A Study of Zilovertamab Vedotin as Monotherapy and in Combination in ...
FDA Okays Phase 3 Study of Zilovertamab in R/R Mantle Cell Lymphoma
(PDF) P1144: PHASE 2 WAVELINE-004 STUDY: ZILOVERTAMAB VEDOTIN (MK-2140 ...
Zilovertamab Vedotin: Merck's Next-Gen ADC Poised to Dominate Relapsed ...
Merck Launches Phase III Trial Evaluating Zilovertamab Vedotin in ...
Zilovertamab Vedotin (MK-2140) in Relapsed or Refractory Diffuse Large ...
Zilovertamab Vedotin Plus Chemo Combo Shows Responses in R/R DLBCL
Zilovertamab Vedotin: Merck's Oncology Breakthrough in DLBCL – A ...
Zilovertamab Vedotin与Polivy I临床数据对比（非头对头） - 2025年03月 - 行业研究数据 - 小牛行研
MSD Presents Zilovertamab Vedotin Results at ASCO Annual Meeting ...
anti-Zilovertamab antibody | Human anti-ROR1 Zilovertamab Monoclonal ...
Trial Work Progressing and Encouraging for Zilovertamab Vedotin Combo ...
Study Comparing Zilovertamab Vedotin with Drug Combination for ...
Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic ...
Zilovertamab (UC-961，泽罗妥单抗) - 仅供科研 | ROR1抑制剂 | MCE
Zilovertamab Vedotin Produces Activity in Heavily Pretreated R/R Mantle ...
Zilovertamab Vedotin Plus R-CHP Yields 97.2% Overall CR Rate in DLBCL
Zilovertamab Vedotin Shows Clinical Activity in Relapsed/Refractory ...
Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse ...
Merck Zilovertamab Shows 100% Remission in DLBCL Trial
VIDEO: Zilovertamab vedotin regimen shows promise in diffuse large B ...
Buy Zilovertamab Biosimilar - Anti-ROR1 mAb - Research Grade Online
A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin ...
Merck's Zilovertamab Vedotin Shows 100% CR Rate in Phase II Study for ...
Merck's Zilovertamab Vedotin: A Breakthrough in Oncology with ...
Zilovertamab Vedotin in DLBCL Patients: Antitumor Activity & Complete ...
Merck's Zilovertamab Vedotin and R-CHP Achieve 100% Complete Response ...
(PDF) The Anti-ROR1 Monoclonal Antibody Zilovertamab Inhibits the ...
Merck’s Investigational Zilovertamab Vedotin in Combination With R-CHP ...
WAVELINE‐004: OPEN‐LABEL, PHASE 2 STUDY OF ZILOVERTAMAB VEDOTIN (MK ...
Zilovertamab vedotin in the treatment of mantle cell lymphoma | VJHemOnc
Zilovertamab: Unlocking the Potential of ROR1-Targeted Therapy - Assay ...
ASH五分钟丨郭晔教授盘点淋巴瘤新药研究-肿瘤瞭望
（淋巴瘤）抗ROR1抗體藥Zilovertamab vedotin有效？
100%CR! 惊为天人! ROR1靶点的ADC——zilovertamab vedotin治疗弥漫大B细胞淋巴瘤-MedSci.cn
默沙东ADC新药Zilovertamab vedotin：DLBCL一线治疗实现100%完全缓解！_摩熵医药(原药融云)
(Zilovertamab vedotin) - 药物靶点：ROR1 x Tubulin_在研适应症：弥漫性大B细胞淋巴瘤，复发性弥漫性大B ...
默沙东：ROR1 ADC报临床，ROR1靶点展现抗癌潜力 - 知乎
【速递】ROR1 ADC治疗1L DLBCL进入3期临床医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Zilovertamab/Ibrutinib Elicits Durable Responses With Favorable ...
国内首家！默沙东申报ROR1抗体偶联药物 11月10日，CDE官网显示， 默沙东 靶向ROR1的抗体偶联药物（ADC）zilovertamab ...
ROR antagonist | ROR inhibitor | ROR agonist | ROR activator
Zilovertamab(Zilovertamab) - 药物靶点：ROR1_在研适应症：套细胞淋巴瘤，慢性淋巴细胞白血病，边缘区B细胞淋巴瘤 ...
Phase 1 Dose Escalation and Cohort Expansion Study of the Anti-ROR1 ...
ROR1，下一个有望成功的肿瘤靶点|肿瘤|治疗|ROR1|CAR-T疗法|-健康界
再発・難治性のびまん性大細胞型B細胞リンパ腫に対するzilovertamab vedotinと標準化学療法の併用、安全かつ良好な奏効率を示す ...
(Zilovertamab vedotin)-药物靶点：ROR1 + Tubulin_在研适应症：弥漫性大B细胞淋巴瘤，B细胞恶性肿瘤，复发性 ...
Anti-ROR1 (zilovertamab biosimilar) mAb-ROR1 Biosimilar mAb for ELISA ...
ROR1靶点ADC药物Zilovertamab Vedotin：DLBCL治疗新突破，完全缓解率达100%
Zilovertamab，anti-ROR1 antibody 抗体 - ChemicalBook
100%CR! 惊为天人! ROR1靶点的ADC——zilovertamab vedotin治疗弥漫大B细胞淋巴瘤@MedSci
Rare intrascrotal tumors in a tertiary cancer center: A retrospective ...
:%0A%0AZilovertamab%20Vedotin%20+%20R-CHP%20for%20Diffuse%20Large%20B-Cell%20Lymphoma.png?md=1)
.png)
.png)
